Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by forhandlarenon Sep 27, 2022 7:27am
159 Views
Post# 34988667

RE:RE:RE:RE:RE:RE:RE:RE:RE:What’s going on?

RE:RE:RE:RE:RE:RE:RE:RE:RE:What’s going on?I don't worry about the CAN wall yesterday, seen this before as a means to make sure that options/warrants issued to management are favourable as calculation is based on average price during a period of time.

One can only speculate about the sellout in Germany today. Within two weeks we should get announcement about the anti-aging clinical trial, an update by means of letter to shareholders and potentially get some insight of the abbvie deal (we don't know when the invoice was cut). Maybe someone was scared of the CAN wall, maybe someone needed the funds to finance something or whatever.

If you deem that company value will be added during the last quarter it's a great opportunity to buy, but I warn you - the investment might double overnight...


<< Previous
Bullboard Posts
Next >>